A clinical trial of a PARP inhibitor drug, Olaparib, based on the approach of synthetic lethality, has given successful results (minimal side effects with safely administrable doses) in breast cancers containing BRCA1/2 mutations [16]. The gene discussed is BRCA1; the disease is breast carcinoma.